MAPT and Alzheimer disease: The detection and diagnosis of AD has been classically based on the evaluation of Aβ and tau biomarkers in the brain (by positron emission tomography – PET) or in the cerebrospinal fluid (CSF) (1, 2), which are either expensive or invasive methods.